Publication:
HLA Alleles Influence the Clinical Signature of Amoxicillin-Clavulanate Hepatotoxicity.

dc.contributor.authorStephens, Camilla
dc.contributor.authorLópez-Nevot, Miguel-Ángel
dc.contributor.authorRuiz-Cabello, Francisco
dc.contributor.authorUlzurrun, Eugenia
dc.contributor.authorSoriano, Germán
dc.contributor.authorRomero-Gómez, Manuel
dc.contributor.authorMoreno-Casares, Antonia
dc.contributor.authorLucena, M Isabel
dc.contributor.authorAndrade, Raul J
dc.contributor.authoraffiliation[Stephens,C; Ulzurrun,E; Lucena,MI; Andrade,RJ] Unidad de Gestión Clínica de Enfermedades Digestivas, Servicio de Farmacología Clínica, Hospital Universitario Virgen de la Victoria. Instituto de Investigación Biomédica de Málaga-IBIMA, Universidad de Málaga, Spain. [López-Nevot,MA; Ruiz-Cabello,F; Moreno-Casares,A] Departamento de Bioquímica y Biología Molecular III/Inmunología, Hospital Universitario Virgen de las Nieves, Universidad de Granada, Spain. [Soriano,G] Servicio de Gastroenterología, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. [Romero-Gómez,M] Unidad de Gestión Clínica de Enfermedades Digestivas, Hospital Universitario de Valme, Universidad de Sevilla, Andalucía Tech, Sevilla, Spain. [Stephens,C; Ulzurrun,E; Soriano,G; Romero-Gómez,M; Lucena,MI; Andrade,RJ] Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain. [Ruiz-Cabello,F] Red Genómica del Cáncer, Madrid, Spain.
dc.date.accessioned2024-01-15T18:17:02Z
dc.date.available2024-01-15T18:17:02Z
dc.date.issued2013-07
dc.description.abstractBACKGROUND AND AIM: The genotype-phenotype interaction in drug-induced liver injury (DILI) is a subject of growing interest. Previous studies have linked amoxicillin-clavulanate (AC) hepatotoxicity susceptibility to specific HLA alleles. In this study we aimed to examine potential associations between HLA class I and II alleles and AC DILI with regards to phenotypic characteristics, severity and time to onset in Spanish AC hepatotoxicity cases. METHODS: High resolution genotyping of HLA loci A, B, C, DRB1 and DQB1 was performed in 75 AC DILI cases and 885 controls. RESULTS: The distributions of class I alleles A*3002 (P/Pc = 2.6E-6/5E-5, OR 6.7) and B*1801 (P/Pc = 0.008/0.22, OR 2.9) were more frequently found in hepatocellular injury cases compared to controls. In addition, the presence of the class II allele combination DRB1*1501-DQB1*0602 (P/Pc = 5.1E-4/0.014, OR 3.0) was significantly increased in cholestatic/mixed cases. The A*3002 and/or B*1801 carriers were found to be younger (54 vs 65 years, P = 0.019) and were more frequently hospitalized than the DRB1*1501-DQB1*0602 carriers. No additional alleles outside those associated with liver injury patterns were found to affect potential severity as measured by Hy's Law criteria. The phenotype frequencies of B*1801 (P/Pc = 0.015/0.42, OR 5.2) and DRB1*0301-DQB1*0201 (P/Pc = 0.0026/0.07, OR 15) were increased in AC DILI cases with delayed onset compared to those corresponding to patients without delayed onset, while the opposite applied to DRB1*1302-DQB1*0604 (P/Pc = 0.005/0.13, OR 0.07). CONCLUSIONS: HLA class I and II alleles influence the AC DILI signature with regards to phenotypic expression, latency presentation and severity in Spanish patients.
dc.description.sponsorshipThis study was supported by the research grant Proyecto Excelencia P10-CTS-6470 and by the Agencia Española del Medicamento. CIBERehd and Red Genómica del Cancer are funded by Instituto de Salud Carlos III
dc.identifier.doi10.1371/journal.pone.0068111
dc.identifier.e-issn1932-6203es_ES
dc.identifier.journalPloS Onees_ES
dc.identifier.otherhttp://hdl.handle.net/10668/1272
dc.identifier.pubmedID23874514es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/17053
dc.language.isoeng
dc.publisherPublic Library of Science (PLOS)
dc.relation.publisherversionhttp://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0068111es
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subjectCombinación Amoxicilina-Clavulanato de Potasio
dc.subjectEnfermedad Hepática Inducida por Drogas
dc.subjectPredisposición Genética a la Enfermedad
dc.subjectHaplotipos
dc.subjectFenotipo
dc.subjectInmunidad Adaptativa
dc.subjectAntibacterianos
dc.subjectGenes Clase I del Complejo de Histocompatibilidad (MHC)
dc.subjectGenes Clase II del Complejo de Histocompatibilidad (MHC)
dc.subjectAntígenos HLA-A
dc.subjectAntígenos HLA-DQ
dc.subjectAntígenos HLA-DR
dc.subjectCadenas beta de HLA-DR
dc.subjectFactores de riesgo
dc.subjectEspaña
dc.subject.meshAmoxicillin-Potassium Clavulanate Combination
dc.subject.meshDrug-Induced Liver Injury
dc.subject.meshGenetic Predisposition to Disease
dc.subject.meshHaplotypes
dc.subject.meshPhenotype
dc.subject.meshAdaptive Immunity
dc.subject.meshAnti-Bacterial Agents
dc.subject.meshGenes, MHC Class I
dc.subject.meshGenes, MHC Class II
dc.subject.meshHLA-A Antigens
dc.subject.meshHLA-DQ Antigens
dc.subject.meshHLA-DR Antigens
dc.subject.meshHLA-DR beta-Chains
dc.subject.meshRisk Factors
dc.subject.meshSpain
dc.titleHLA Alleles Influence the Clinical Signature of Amoxicillin-Clavulanate Hepatotoxicity.
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isPublisherOfPublicationa2759e3d-0d58-4e8a-9fcd-c6130ee333d1
relation.isPublisherOfPublication.latestForDiscoverya2759e3d-0d58-4e8a-9fcd-c6130ee333d1

Files